ExaGrid Voted “Hyper-converged Backup and Recovery Product of the Year” in 2017 SVC Awards
ExaGrid®, a leading provider of hyper-converged secondary storage (HCSS) for backup with data deduplication, today announced that its EX series of appliances has been honored by SVC with its 2017 Hyper-converged Backup and Recovery Product of the Year award. Winners were announced at the SVC Awards Gala Ceremony on November 23 in London, UK.
The SVC Awards recognize the products, projects and services – as well as honor companies and teams – operating with excellence in the cloud, virtualization, and storage sectors. The SVC Awards also recognize the achievements of end users, channel partners, and vendors.
The ExaGrid EX series of appliances is a hyper-converged secondary storage system for backup that revolutionizes how organizations back up and protect data. ExaGrid’s scale-out backup storage systems deduplicate and store data from over 25 industry-leading backup software applications. ExaGrid’s backup storage appliances have been architected from the ground up specifically for backup storage to address today’s demanding backup requirements and are optimized for superior backup and recovery performance for both physical and virtual IT environments.
“We are honored to have been chosen as the 2017 SVC Hyper-converged Backup and Recovery Product of the Year,” said Bill Andrews, CEO of ExaGrid. “We believe it reflects ExaGrid’s position as the premier hyper-converged secondary storage solution for backup that as part of its very architecture solves the myriad of performance challenges inherent to deduplication for backups, restores, and VM boots. ExaGrid’s unique landing zone and scale-out backup storage is 3 times faster for ingest and over 20 times faster for restores and VM boots than its closest competitor. In addition, ExaGrid is the only solution that provides a fixed-length backup window as data grows. With ExaGrid, IT can have the fastest backups, restores, and VM boots; a fixed-length backup window; and the ability to easily scale their systems, so they simply buy what they need as they need it, all at the lowest cost up front and over time. ExaGrid eliminates forklift upgrades and product obsolescence.”
According to Jason Holloway, Director of IT Publishing at Angel Business Communications, publishers of the Digitalisation World stable of titles, “Nominations for the SVC Awards 2017 were of very high quality and there was also a significant increase in the numbers of votes cast. The SVC Awards recognize the users, manufacturers and suppliers operating in the storage, virtualization and cloud sectors and are voted for by the readers of our wide range of print and online publications. All finalists did well in reaching the high standard shortlist, but ExaGrid was the clear winner in its category.”
ExaGrid’s EX40000E is the largest in the company’s product line and scales from a 40TB full backup up to a 1PB full backup by combining 25 EX40000Es in a single scale-out system. The ingest rate of a full single system is 200TB/hr., which is 3 times the ingest performance of the EMC Data Domain 9800 with DD Boost. ExaGrid’s unique landing zone not only allows for the fastest backups but also for the fastest restores and VM boots as ExaGrid maintains the most recent backup in its full undeduplicated form. ExaGrid is the only vendor that adds compute with capacity versus just adding disk shelves. This scale-out approach allows for performance to be added along with capacity growth, which provides for a fixed-length backup window as data grows.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
Christine Murphy, 508-898-2872 x248
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an